BerGenBio (OB:BGBIO) - Cotización, noticias y análisis

Resumen de acción BGBIO

BerGenBio ASA, empresa biofarmacéutica en fase clínica, se dedica al desarrollo de nuevos medicamentos para tratar cánceres inmunoevasivos, resistentes a fármacos y metastásicos, así como enfermedades respiratorias.

Acerca de la empresa

BGBIO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene menos de 1 año de cash runway

Alta volatilidad del precio de la acción en los últimos 3 meses

Se prevé que los beneficios disminuyan un promedio de 19.9% al año durante los próximos 3 años

Los accionistas han sido diluidos sustancialmente en el último año

+ 3 riesgos adicionales

Competidores de BerGenBio ASA

Thor Medical

OB:TRMED

kr241.9m

Ultimovacs

OB:ULTI

kr241.5m

Nordic Nanovector

OB:NANOV

kr231.8m

Norda

OTCNO:NORD

kr203.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for BerGenBio
Historical stock prices
Current Share Price	kr0.13
52 Week High	kr0.49
52 Week Low	kr0.075
Beta	1.44
1 Month Change	-16.65%
3 Month Change	-40.90%
1 Year Change	-49.54%
3 Year Change	-99.44%
5 Year Change	-99.40%
Change since IPO	-99.48%

Noticias y actualizaciones recientes

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07

Recent updates

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21

Rentabilidad de los accionistas

	BGBIO	NO Biotechs	Mercado NO
7D	5.0%	2.4%	-0.2%
1Y	-49.5%	-56.8%	7.7%

Rentabilidad vs. Industria: BGBIO superó a la industria Norwegian Biotechs, que obtuvo un rendimiento del -56.8% el año pasado.

Rentabilidad vs. Mercado: BGBIO obtuvo unos resultados inferiores a los del mercado Norwegian, que fue del 4.6% el año pasado.

Volatilidad de los precios

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement	11.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	4.9%
10% most volatile stocks in NO Market	10.4%
10% least volatile stocks in NO Market	3.1%

Precio estable de las acciones: El precio de las acciones de BGBIO ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BGBIO ha disminuido de 26% a 13% en el último año, pero sigue siendo superior al 75% de los valores de Norwegian.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	25	Martin Olin	www.bergenbio.com

BerGenBio ASA, empresa biofarmacéutica en fase clínica, se dedica al desarrollo de medicamentos novedosos para tratar cánceres inmunoevasivos, resistentes a fármacos y metastásicos, así como enfermedades respiratorias. Desarrolla el bemcentinib, un inhibidor oral una vez al día de la tirosina quinasa receptora AXL, que se encuentra en ensayo clínico de fase 1b/2a para tratar el cáncer de pulmón no microcítico, y en ensayo clínico de fase 2 para tratar la leucemia mieloide aguda y la COVID-19. El bemcentinib también se está estudiando para el glioblastoma, el cáncer de pulmón 2L, el melanoma, el cáncer de páncreas y el mesotelioma.

Resumen de fundamentos de BerGenBio ASA

¿Cómo se comparan los beneficios e ingresos de BerGenBio con su capitalización de mercado?
Estadísticas fundamentales de BGBIO
Capitalización bursátil	kr512.82m
Beneficios(TTM)	-kr190.40m
Ingresos (TTM)	kr354.00k

1,449x

Ratio precio-ventas (PS)

-2.7x

Ratio precio-beneficio (PE)

¿Está BGBIO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BGBIO
Ingresos	kr354.00k
Coste de los ingresos	kr0
Beneficio bruto	kr354.00k
Otros gastos	kr190.76m
Beneficios	-kr190.40m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 29, 2024

Beneficios por acción (BPA)	-0.049
Margen bruto	100.00%
Margen de beneficio neto	-53,785.59%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BGBIO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BGBIO

Recompensas

Análisis de riesgos

Competidores de BerGenBio ASA

OB:TRMED

kr241.9m

OB:ULTI

kr241.5m

OB:NANOV

kr231.8m

OTCNO:NORD

kr203.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

Recent updates

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Price target decreased by 63% to kr5.68

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

Price target decreased to kr12.00

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to kr47.50

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

New 90-day low: kr30.75

Analysts update estimates

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Revenue and earnings in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

Price target raised to kr63.00

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: kr37.30

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021